Ajay Nirula News Today

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ --...

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to ...

INDIANAPOLIS, Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company today announced the successful completion of its acquisition of DICE Therapeutics, Inc. . The acquisition expands Lillys immunology...

This is the first clinical evidence to show that stimulating the programmed cell death protein 1 (PD1) inhibitory pathway is beneficial for rheumatologic disease.

Results of a Phase 2a clinical trial suggest that peresolimab, an antibody that stimulates the human death protein 1 (PD-1) pathway, could be a promising new approach for the treatment of rheumatoid arthritis.

An investigational drug may hit the reset button on a faulty immune system for some people with rheumatoid arthritis.

At the 12-week mark, the change from baseline in the DAS28-CRP was significantly greater in patients with rheumatoid arthritis receiving 700 mg peresolimab when compared with the placebo group.

NEW ORLEANS — A novel monoclonal antibody could be a promising treatment for hidradenitis suppurativa as phase 2 clinical trial results showed an improvement in total abscess and nodule count after 16 weeks of treatment. Eltrekibart (LY3041658, Eli Lilly) is a humanized monoclonal antibody that binds to the seven ligands that signal through CXCR1 and CXCR2, according to Seth Forman, MD,

/PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today...

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., Aug. 25, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement